• Open Access

Splicing in oncogenesis and tumor suppression

Authors

  • Daisuke Kaida,

    1. Frontier Research Core for Life Sciences, University of Toyama, Toyama, Japan
    Search for more papers by this author
  • Tilman Schneider-Poetsch,

    1. Chemical Genetics Laboratory/Chemical Genomics Research Group, RIKEN Advanced Science Institute, Wako, Saitama, Japan
    Search for more papers by this author
  • Minoru Yoshida

    Corresponding author
    1. Chemical Genetics Laboratory/Chemical Genomics Research Group, RIKEN Advanced Science Institute, Wako, Saitama, Japan
    2. Japan Science and Technology Corporation (JST), CREST Research Project, Kawaguchi, Saitama, Japan
    • Frontier Research Core for Life Sciences, University of Toyama, Toyama, Japan
    Search for more papers by this author

To whom correspondence should be addressed.

E-mail: yoshidam@riken.jp

Abstract

Post-transcriptional modifications, such as 5′ end capping, 3′ end polyadenylation and splicing, are necessary for the precise regulation of gene expression and transcriptome integrity. Therefore, it is not surprising that abnormalities of these post-transcriptional modifications prompt numerous diseases, including cancer. In fact, many studies revealed that misregulation of mRNA processing, especially splicing, are observed in a variety of cancer cells. In this review we describe how changes within RNA splicing regulatory elements or mutations in the processing factors alter the expression of tumor suppressors or oncogenes with pathological consequences. In addition, we show how several small molecules that bind to spliceosomal components and splicing regulators inhibit or modulate splicing activity. These compounds have anticancer activity and further development of small molecule modulators has potential in next generation cancer therapy.

Ancillary